AbbVie's Subcutaneous Skyrizi Shows Endoscopic Benefits In Crohn's Diseases
(RTTNews) - Tuesday, AbbVie reported new Phase 3 AFFIRM data showcasing endoscopic outcomes with subcutaneous Skyrizi in adults with moderately to severely active Crohn's disease.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
